Intestinal ph and gastrointestinal transit profiles in cystic fibrosis patients measured by wireless motility capsule

Digestive Diseases and Sciences

Volumn 58, Issue 8, 2013, Pages 2275-2281

  Gelfond, Daniel ^a   Ma, Changxing ^b   Semler, Jack ^c   Borowitz, Drucy ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c SmartPill Corporation   (United States)

Author keywords

CFTR; Cystic fibrosis; PERT; pH profile; Small bowel transit; Wireless motility capsule

Indexed keywords

PANCREAS ENZYME;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISSOLUTION; FEMALE; GASTROINTESTINAL TRANSIT; HUMAN; INTESTINE; MALE; PH MEASUREMENT; PRIORITY JOURNAL; SMALL INTESTINE; STOMACH EMPTYING; WIRELESS MOTILITY CAPSULE;

ADOLESCENT; ADULT; CAPSULE ENDOSCOPY; CYSTIC FIBROSIS; FEMALE; GASTROINTESTINAL MOTILITY; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINES; MALE; PILOT PROJECTS; YOUNG ADULT;

EID: 84881476486     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2209-1     Document Type: Article

References (23)

1. Ferrone M, Raimondo M, Scolapio JS. Pancreatic enzyme pharmacotherapy. Pharmacotherapy. 2007;27:910-920.
2. Kraisinger M, Hochhaus G, Stecenko A, Bowser E, Hendeles L. Clinical pharmacology of pancreatic enzymes in patients with cystic fibrosis and in vitro performance of microencapsulated formulations. J Clin Pharmacol. 1994;34:158-166.
3. Garcia MA, Yang N, Quinton PM. Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. J Clin Invest. 2009;119:2613-2622.
4. Chen EY, Yang N, Quinton PM, Chin WC. A new role for bicarbonate in mucus formation. Am J Physiol Lung Cell Mol Physiol. 2010;299:L542-L549.
5. Couper RT, Corey M, Moore DJ, Fisher LJ, Forstner GG, Durie PR. Decline of exocrine pancreatic function in cystic fibrosis patients with pancreatic sufficiency. Pediatr Res. 1992;32:179-182.
6. Clarke LL, Harline MC. Dual role of CFTR in cAMP-stimulated HCO3- secretion across murine duodenum. Am J Physiol. 1998;274:G718-G726.
7. Pratha VS, Hogan DL, Martensson BA, Bernard J, Zhou R, Isenberg JI. Identification of transport abnormalities in duodenal mucosa and duodenal enterocytes from patients with cystic fibrosis. Gastroenterology. 2000;118:1051-1060.
8. Dutta SK, Hubbard VS, Appler M. Critical examination of therapeutic efficacy of a pH-sensitive enteric-coated pancreatic enzyme preparation in treatment of exocrine pancreatic insufficiency secondary to cystic fibrosis. Dig Dis Sci. 1988;33:1237-1244.
9. Youngberg CA, Berardi RR. Comparison of gastrointestinal pH in cystic fibrosis and healthy subjects. Dig Dis Sci. 1987;32:472-480.
10. Borowitz D, Durie PR. Gastrointestinal outcomes and confounders in cystic fibrosis. J Pediatr Gastroenterol Nutr. 2005;41:273-285.
11. Waldum HL, Qvigstad G, Fossmark R, Kleveland PM, Sandvik AK. Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint. Scand J Gastroenterol. 2010;45:389-394.
12. Hasler WL, Coleski R. Differences in intragastric pH in diabetic vs. idiopathic gastroparesis: relation to degree of gastric retention. Am J Physiol Gastrointest Liver Physiol. 2008;294:G1384-G1391.
13. Rao SSC, Kuo B, McCallum RW, et al. Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation. Clinical gastroenterology and hepatology: the official clinical practice. Am J Gastroenterol. 2009;7(5):537-44.
14. Kuo B, McCallum RW. Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. Aliment Pharmacol Ther. 2008;27:186-196.
15. Kaunitz JD, Akiba Y. Review article: duodenal bicarbonate - mucosal protection, luminal chemosensing and acid-base balance. Aliment Pharmacol Ther. 2006;24:169-176.
16. Allen A, Flemstrom G. Gastroduodenal mucus bicarbonate barrier: protection against acid and pepsin. Am J Physiol Cell Physiol. 2005;288:C1-C19.
17. Steward MC, Ishiguro H. Molecular and cellular regulation of pancreatic duct cell function. Curr Opin Gastroenterol. 2009;25:447-453.
18. Montrose MHA, Yasutada TK, Kaunitz JD. Gastroduodenal mucosal defense. In: Johnson LR, eds. Physiology of the Gastrointestinal Tract. Amsterdam: Elsevier; 2006:1260-1291.
19. Clarke LL, Stien X, Walker NM. Intestinal bicarbonate secretion in cystic fibrosis mice. JOP. 2001;2:263-267.
20. Tovar JA, Izquierdo MA, Eizaguirre I. The area under pH curve: a single-figure parameter representative of esophageal acid exposure. J Pediatr Surg. 1991;26:163-167.
21. Proesmans M, De Boeck K. Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes. Eur J Pediatr. 2003;162:760-763.
22. Canani RB, Cirillo P. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics. 2006;117:e817-e820.
23. Ramsey BW, Davies J. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365:1663-1672.